FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Investigación/Highlighting the clinical significance of responder analyses in determining the efficacy of bremelanotide for treating HSDD and FSAD.
Volver a Biblioteca de Investigación
bremelanotideHSDDFSAD

Highlighting the clinical significance of responder analyses in determining the efficacy of bremelanotide for treating HSDD and FSAD.

May 17, 2026
Share

Fuente del Paper

Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

Althof Stanley et al.The journal of sexual medicine2019
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo descompone los hallazgos del paper fuente anterior en lenguaje accesible para la comunidad de investigación de péptidos. Nuestro objetivo es destacar lo más importante — las implicaciones prácticas, la fuerza de la evidencia y lo que significa para la investigación en curso.

Bremelanotide Shows Promise in Treating Sexual Dysfunction: A Closer Look at Responder Analyses

Published: May 17, 2026 | Source: The journal of sexual medicine (2019) | Category: bremelanotide, HSDD, FSAD

Overview

A recent study published in The Journal of Sexual Medicine has provided valuable insights into the efficacy of bremelanotide for treating hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). The research highlights the importance of responder analyses in clinical trials to determine meaningful improvements in patient-reported outcomes. This paper underscores the potential benefits of bremelanotide for premenopausal women suffering from these conditions.

Study Background

Prior to this study, there was a need for more robust data on effective treatments for HSDD and FSAD, particularly in identifying clinically significant changes that improve patients' quality of life. Bremelanotide is a melanocortin receptor agonist being investigated as a potential therapy for sexual dysfunction. This phase 2b dose-ranging study aimed to establish the minimal clinically important difference (MCID) for various patient-reported outcomes and assess bremelanotide's efficacy compared to placebo.

What the Research Found

The study involved premenopausal women with HSDD or mixed HSDD/FSAD, focusing on changes in sexual function over a period of treatment. Key findings include:

  • Significant improvements were observed at the 1.75 mg dose of bremelanotide for seven endpoints compared to placebo (P ≤ .03).
  • Responder rates indicated that patients experienced meaningful benefits based on multiple types of analyses, including those anchored to historical anchors and self-reported global benefit.
  • The results provided a basis for further clinical trials by identifying the MCID for various measures of sexual function.

What This Means for Peptide Users

For individuals considering bremelanotide as part of their treatment plan, these findings suggest that it may offer significant benefits in enhancing sexual desire and arousal. However, it is crucial to consult with a healthcare provider before starting any new therapy, especially given the specific population studied (premenopausal women) and the need for further validation through phase 3 trials.

Limitations and Caveats

While the study provides promising results, several limitations must be acknowledged:

  • The research was conducted on a relatively small sample size compared to what would be expected in larger-scale phase 3 studies.
  • The analysis is specific to premenopausal women with HSDD or FSAD, limiting its generalizability to other populations or conditions.
  • Further validation through additional clinical trials is necessary before broader recommendations can be made.

How This Compares to Previous Research

This study builds upon earlier research that established the potential of bremelanotide for treating sexual dysfunction. However, it provides a more detailed analysis by focusing on responder rates and clinically meaningful differences, which adds depth to our understanding of how this peptide might benefit patients in real-world settings.

Our Analysis

At PeptideVault, we view this study as an important step forward in the development of effective treatments for HSDD and FSAD. The use of multiple types of responder analyses strengthens the reliability of the findings. However, due to the limitations noted, it is essential that future research continues to explore bremelanotide's efficacy across broader populations.

Key Takeaways

  • Bremelanotide at a dose of 1.75 mg showed significant improvements in sexual function compared to placebo.
  • The study highlights the importance of responder analyses for subjective endpoints like those related to sexual health.
  • Further research is needed before definitive conclusions can be drawn about bremelanotide's efficacy and safety.

Original Source

Citation: Althof Stanley, Derogatis Leonard R, Greenberg Sally et al. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.. The journal of sexual medicine. DOI: 10.1016/j.jsxm.2019.05.012

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue preparado por el equipo de investigación de Peptide Contacts. Se anima a los lectores a revisar la fuente completa del paper para metodología y datos completos. La publicación original está disponible en PubMed.

Comments

Sign in to join the discussion

Este análisis se genera a partir de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.